Natco Pharma receives USFDA approval for Erdafitinib, a generic cancer drug for advanced urothelial carcinoma patients.

Drug firm Natco Pharma on Tuesday said it has received approval from the US health regulator for a generic cancer medication.

Natco Pharma has received U.S. Food and Drug Administration’s tentative approval for Erdafitinib Tablets 3 mg, 4mg, and 5 mg, a generic version of Janssen Biotech cancer drug Balversa.

MUMBAI (Reuters) - Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill ...

NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa by Janssen Biotech Inc.

Natco Pharma on Monday said its marketing partner Breckenridge Pharmaceutical Inc has received approval from the US health regulator for anti-cancer drug Carfilzomib Vials. "Breckenridge ...

Natco Pharma announced that through its affiliates it is proposing to enter into an agreement to acquire Dash Pharmaceuticals subject to satisfactory completion of due diligence, execution of ...

Yet another Indian drugmaker has had plants written up by the FDA for not hitting manufacturing standards. This time it is Natco Pharma, which said it got Form 483s for its pharmaceutical formulations ...

HOUSTON, July 20 /PRNewswire-FirstCall/ -- NATCO Group Inc. (NYSE: NTG) announced today that it has sold shares representing twenty-five percent ownership in its ...

NATCO Pharma Limited on Tuesday said it has received tentative approval from the US Food and Drug Administration (USFDA) for ...